Fructo-oligosaccharides (FOS) are widely used in commercial food products. Most studies on FOS concern the health benefits, but some negative effects were recently reported concerning the faecal cytotoxicity and excretion of mucin-type oligosaccharides in combination with a Ca-restricted diet. The present study was performed to investigate whether these effects of FOS are observed in adults consuming a regular diet unrestricted in Ca. The study was a randomised, double-blind, placebo-controlled crossover trial, involving eleven healthy adults, who consumed 25–30 g FOS or maltodextrin (control) in a random order for 2 weeks in addition to their regular diet. Stools were collected for analysis of pH and SCFA (as markers of fermentation), for the assessment of faecal water cytotoxicity, and for the analysis of alkaline phosphatase activity (as a marker of epithelial cell turnover) and O-linked oligosaccharides (to estimate the excretion of mucin-type oligosaccharides). FOS consumption significantly altered bacterial fermentation (increased percentage of acetate, decreased percentage of butyrate) and tended to decrease stool pH. Furthermore, FOS consumption resulted in a significantly higher stool frequency and in significantly more complaints of flatulence. No significant differences between the control and FOS period were observed in the mean cytotoxicity of faecal water (37·5 (SEM 6·9) % of epithelial cell turnover) and O-linked oligosaccharides (to estimate the excretion of mucin-type oligosaccharides). We conclude that dietary FOS in a dose up to 25–30 g/d altered the bacterial fermentation pattern but did not affect faecal cytotoxicity or the faecal concentration of mucin-type oligosaccharides in human adults consuming a regular diet.

Fructo-oligosaccharides: Man: Cytotoxicity: Mucin: Alkaline phosphatase

Although most studies on the effect of FOS and inulin concern their health benefits, recent papers by the same group have reported that short-chain FOS (degree of polymerisation 2–7) in combination with a diet low in Ca were associated with an impairment in the resistance of rats to intestinal Salmonella infection (Bovee-Oudenhoven et al. 2003; Ten Bruggencate et al. 2003, 2004a). Prior to infection, an increased cytotoxicity of faecal water and an increased faecal excretion of mucin (estimated on the basis of faecal excretion of O-linked oligosaccharides) was observed in all three studies. In one of these studies (Ten Bruggencate et al. 2004a), it was shown that dietary Ca abolished the presumed detrimental effect of FOS. A recent study examined healthy males receiving a diet restricted in Ca (mean intake 298–315 mg Ca/d) and supplemented with 20 g FOS or with 20 g sucrose for 2 weeks (Ten Bruggencate et al. 2004b). This study could not confirm the finding of the rat studies, with respect to the cytotoxicity of faecal water, but increased levels...
of mucin-type glycoproteins were observed in the faecal samples.

As FOS are included in many functional foods and nutritional products for their beneficial health effects, it is important to verify the observations mentioned above in human subjects receiving a regular diet, unrestricted in Ca. We therefore performed a randomised, double-blind, placebo-controlled crossover trial in which the effect of high doses of dietary short-chain FOS on the cytotoxicity of faecal water, on the activity of alkaline phosphatase (ALP) and on the faecal content of 0-linked oligosaccharides was evaluated in healthy adults who maintained their regular diet.

Materials and methods

Subjects

Twelve healthy subjects, six men and six women, aged 18–35 years were eligible for inclusion in the study. None suffered from gastrointestinal disease or had a history of gastrointestinal disease. They did not use any products containing added prebiotic oligosaccharides, probiotic bacteria or added fibre. None of the participants was pregnant or lactating, or had been using antibiotics and/or laxative drugs (for up to 3 months before inclusion).

Study design

The study was a randomised, double-blind, placebo-controlled crossover trial with two study periods separated by a wash-out period. Healthy adults were recruited via advertisements and posters in the region of Wageningen, The Netherlands. Participation in the study was voluntary, and written informed consent was obtained before the start of the study.

During a pre-trial visit to the participants in their homes, a small questionnaire with questions on the use of nutritional products for their beneficial health effects, it is important to verify the observations mentioned above in human subjects receiving a regular diet, unrestricted in Ca. We therefore performed a randomised, double-blind, placebo-controlled crossover trial in which the effect of high doses of dietary short-chain FOS on the cytotoxicity of faecal water, on the activity of alkaline phosphatase (ALP) and on the faecal content of 0-linked oligosaccharides was evaluated in healthy adults who maintained their regular diet.

During the study period, a study diary was filled in with questions on the frequency and consistency of stools, medicine intake and gastrointestinal complaints (constipation, diarrhoea, flatulence, bloating, stomach ache, cramps, nausea, regurgitations, vomiting). The consistency of stools was rated on a five-point scale (1 = watery, 2 = soft, pudding-like, 3 = soft, formed, 4 = dry, formed, 5 = dry, hard pellets), and gastrointestinal complaints were rated on a four-point scale (1 = none, 2 = mild, 3 = moderate, 4 = severe). In addition, deviations from regular food intake were recorded in the ‘remarks’ section of the study diary. At the end of the 2-week intervention periods, the participants were asked to collect their stools on three consecutive days (days 12, 13 and 14, and days 40, 41 and 42). All stools were stored at −20°C until transport to Numico Research. The study was approved by the Medical Ethics Committee of the Radboud University Nijmegen Medical Centre in Nijmegen.

Biochemical analysis of faeces

Preparation of faecal samples. After storage at −20°C, all individual 3-d stool collections were thawed at 4°C, pooled and homogenised, and the total wet weight was determined. A part of the pooled faeces was freeze dried for further analyses, and the percentage dry weight was determined.

Measurements of pH. Wet faeces were diluted five times in saline, and the pH was measured directly in faeces at room temperature using a Handylab pH meter (Schott Glas, Mainz, Germany) equipped with an Inlab 423 pH electrode (Mettler-Toledo, Tiel, The Netherlands).

SCFA and lactate. For the determination of SCFA, wet faeces were thawed in ice water, diluted 10 times (w/v) in milliQ double-distilled water and homogenised for 10 min using a stomacher (IUL Instruments, Barcelona, Spain). Homogenised faeces 350 µl were mixed with 200 µl 5 % (v/v) formic acid, 100 µl 1·25 g/l 2-ethylbutyric acid (Sigma-Aldrich, Zwijndrecht, The Netherlands) and 350 µl milliQ water. The samples were centrifuged for 5 min at 16 000 g to remove large particles, and the supernatant was stored at −20°C. SCFA (acetic, propionic, n-butyric acids) were quantitatively determined as described previously by using gas chromatography with 2-ethylbutyric acid as an internal standard (Knol et al. 2004), and were expressed as µmol/g wet faeces. For the lactate analyses, faecal samples were diluted two times in PBS (pH 7·4) and homogenised using a stomacher IUL Instruments, Barcelona, Spain. Thereafter, the concentrations of L- and D-lactate in the samples were determined spectrophotometrically with l- and d-lactic acid enzyme kits (Scil Diagnostics GmbH, Viernheim, Germany). The results for lactate are expressed as µmol/g wet faeces.

Cytotoxicity of faecal water. Faecal water was prepared by reconstitution of freeze-dried faeces with double-distilled water at a final concentration of 20 % w/v. After incubation for 1 h at 37°C, the samples were centrifuged for 30 min at 10 000 g. Supernatants were then centrifuged for 10 min at 10 000 g. Osmolality was measured to assure physiological ionic strength (300 mOsm/kg). The samples were stored at −20°C until analysis.

Cytotoxicity was evaluated as previously described, with minor changes (Govers & Van der Meer, 1993). Increasing volumes of faecal water were buffered with 100 mM-MOPS (3-N-morpholino-propanesulfonic acid) buffer, pH 7·4, to a total volume of
80 µl. After preincubation for 5 min at 37°C, 20 µl of a washed human erythrocyte suspension was added (final haematocrit 5%) and incubated for 2 h at 37°C. The intact erythrocytes were precipitated by centrifugation for 1 min and washed twice with 154 mM-NaCl. After acidification with TCA (final 5% w/v) and subsequent centrifugation, the K content of the supernatant was measured by atomic emission spectrophotometry (Atomic Absorption Spectrophotometer 3030; Perkin Elmer, Life and Analytical Sciences Inc., Wellesley, MA 02481-4078, USA). Simultaneously, erythrocytes were incubated in 154 mM-NaCl (0% haemolysis) and in double-distilled water (100% haemolysis). The percentage haemolysis was calculated as the area under the activity for ALP activity was expressed as U/g dry faeces.

Statistical analysis

The study was a randomised, double-blind, placebo-controlled crossover trial, with two treatment periods involving two groups of six participants in each period. A power calculation indicated that a sample size of twelve healthy adults was necessary to detect a statistically significant difference in faecal water cytotoxicity of 25%, assuming a standard deviation of 22%, with a power of 0.8 and a two-sided significance level of 0.05 (Raftel et al. 1987).

All data were analysed with an ANOVA model with the product (control or FOS), the period (first or second) and the product sequence (FOS then control, or control then FOS) as fixed factors, and subjects as a nested factor (Jones & Kenward, 2003). Normality was checked with the Shapiro–Wilk test of normality on the residuals. Means of the questionnaire data on stool characteristics and gastrointestinal complaints were calculated for the second week of intervention. The data from the run-in period were not included in the analysis. There appeared to be no significant carry-over or period effects, and therefore the data from the treatments in the two periods were pooled. The results of the product periods were expressed as means with their standard errors, and the 95% CI of the difference. All statistical analyses have been performed with SPSS version 12.0.1 (SPSS Inc., Chicago, IL, USA). Differences between the product groups were considered statistically significant at P < 0.05.

Results

All twelve participants (six men, six women) completed the study. The mean age at enrolment was 21.4 (SD 2.0) years, and mean weight and height were 66.4 kg (SD 8.3 kg) and 1.79 m (SD 0.08 m) respectively. One stool collection was missing in the analysis owing to the unexpected absence of the participant during the time of the sampling. Hence, the results of eleven participants are presented. Compliance, determined by counting the number of unused sachets at the end of the study period, was high (98.4%), indicating that the prescribed daily dose (25–30 g) was achieved throughout the study periods.

Stool characteristics and gastrointestinal symptoms

Stool results are shown in Table 1. Stool frequency was significantly higher in the FOS period compared with the control period, with a mean stool frequency of 1.2 (SEM 0.06) per day in the control period and 1.5 (SEM 0.15) per day in the FOS period (P = 0.014). Total stool output tended to be higher in the FOS period (F(1.9) = 3.4, P = 0.097), and stool consistency was similar in both periods (F(1.10) = 0.3, P = 0.607).

In the control group, mild gastrointestinal complaints were recorded thirty-one times, and moderate complaints were recorded twice (stomach ache once, flatulence once). Severe complaints were not recorded. In the FOS group, mild gastrointestinal complaints were reported twenty-nine times, and moderate complaints were reported twenty-four times (diarrhoea four times (one subject 3 d, one subject 1 d), stomach ache twice (one subject 2 d), bloating three times (three subjects 1 d), flatulence ten times (one subject 3 d, two subjects 2 d, three subjects 1 d), nausea once, and cramps four times (two subjects 2 d)). Severe complaints were reported eleven times (diarrhoea once, stomach ache twice (two subjects 1 d), bloating once, flatulence seven
times (one subject 1 d, one subject 6 d), and cramps once). No significant differences between the control and the FOS period were observed in the mean occurrence of these complaints, except for flatulence: in the FOS period, participants recorded a significantly higher score of flatulence compared with the control period (with a mean score of 1.8 (SEM 0.18) in the control period and 1.2 (SEM 0.18) in the control period; F(1,10) = 5.6, P = 0.039).

### pH, SCFA and lactate in stools

There was a trend towards a lower stool pH in the FOS period compared with the control period (F(1,9) = 4.4, P=0.065). The proportions of SCFA changed owing to FOS supplementation, with higher proportions of acetate (F(1,9) = 11.2, P=0.009) and lower proportions of butyrate (F(1,9) = 17.1, P=0.003). No major differences were observed in the concentration of total SCFA in the faeces. Faecal lactate concentrations were higher in the FOS group, but the difference was not statistically significant (F(1,9) = 0.7, P=0.376). The results are shown in Table 2.

### Cytotoxicity of faecal water, alkaline phosphatase activity and faecal contents of O-linked oligosaccharides

FOS tended to reduce the cytotoxicity of faecal water, with mean cytotoxicity levels of 37.5 (SEM 6.9)% and 18.5 (SEM 6.9)% in the control period and the FOS period, respectively (F(1,9) = 3.8, P=0.084; Fig. 1). No difference was observed in mean faecal ALP activity in the control treatment period (27.7 (SEM 2.9) U/g dry faeces) and the FOS treatment period (24.6 (SEM 3.2) U/g dry faeces; F(1,9) = 0.5, P=0.496; Fig. 2). In the same faecal samples, the amount of O-linked oligosaccharide in the faeces was determined to estimate faecal mucin content (Fig. 3). The mean faecal excretion of O-linked oligosaccharides in the control and the FOS periods was 49.9 (SEM 4.0) and 53.5 (SEM 4.3) mg/g dry faeces, respectively. No statistical significant difference was observed (F(1,9) = 0.4, P=0.553).

### Discussion

Our results demonstrate that the cytotoxicity of faecal water, faecal ALP activity and the faecal concentration of mucin-type oligosaccharides were not affected by the intake of dietary FOS in healthy adults with a regular diet unrestricted in Ca.

FOS were provided for 2 weeks, with a run-in of 1 week in each period. The dose of FOS used in the current study was 25–30 g/d, which in Europe is far above the estimated mean daily intake of FOS and inulin from natural sources, namely 3.2–11.3 g, with peak values of up to 20 g (Van Loo, 1995). FOS are resistant to hydrolysis by human small intestinal enzymes and enter the colon intact. In the colon, FOS are fermented by intestinal bacteria, and several studies have demonstrated an increase in the intestinal bifidobacterium count within a few weeks of supplementation with FOS (Gibson et al. 1995; Bouhnik et al. 1996, 1999; Buddington et al. 1996; Kleessen et al. 1997; Tuohy et al. 2001). End products of fermentation by bifidobacteria include lactate, SCFA (in particular acetate) and gases such as CO2 and H. An analysis of these end products in faeces gives an indication of bacterial fermentation.

In our study, FOS affected bacterial fermentation, as observed by a trend towards a lower pH, a statistically significant higher proportion of acetate and a tendency towards higher levels of lactate. Furthermore, FOS intake resulted in a more frequently reported occurrence of flatulence, a higher stool frequency and a trend towards a higher stool output, all

### Table 1. Effects of dietary fructo-oligosaccharides (FOS) and maltodextrin (control) on pH, SCFA and lactate in stools of healthy adults (n 11 for stool output and percentage dry weight, n 12 for stool frequency and stool consistency)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Control period</th>
<th>FOS period</th>
<th>95% CI of the difference (F, P)</th>
</tr>
</thead>
<tbody>
<tr>
<td>pH</td>
<td>6.6 (0.16)</td>
<td>6.1 (0.18)</td>
<td>−0.0 to 1.0 (F(1,9) = 4.4, P=0.065)</td>
</tr>
<tr>
<td>Lactate (µmol/g wet faeces)</td>
<td>5.6 (1.7)</td>
<td>8.0 (2.0)</td>
<td>−8.6 to 3.6 (F(1,9) = 0.7, P=0.376)</td>
</tr>
<tr>
<td>Total SCFA (µmol/g wet faeces)</td>
<td>97.3 (6.7)</td>
<td>90.6 (7.4)</td>
<td>−15.8 to 29.3 (F(1,9) = 0.5, P=0.517)</td>
</tr>
<tr>
<td>Acetate (% of total SCFA)</td>
<td>62.0 (2.0)</td>
<td>72 (2.2)</td>
<td>−16.9 to −3.3 (F(1,9) = 11.2, P=0.009)</td>
</tr>
<tr>
<td>Propionate (% of total SCFA)</td>
<td>17.5 (1.3)</td>
<td>14.9 (1.4)</td>
<td>−1.9 to 7.0 (F(1,9) = 1.7, P=0.224)</td>
</tr>
<tr>
<td>Butyrate (% of total SCFA)</td>
<td>22.5 (1.2)</td>
<td>15.0 (1.4)</td>
<td>3.4 to 11.7 (F(1,9) = 17.1, P=0.003)</td>
</tr>
</tbody>
</table>

### Table 2. Effects of dietary fructo-oligosaccharides (FOS) and maltodextrin (control) on pH, SCFA and lactate in the faeces of healthy adults (n 11)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Control period</th>
<th>FOS period</th>
<th>95% CI of the difference (F, P)</th>
</tr>
</thead>
<tbody>
<tr>
<td>pH</td>
<td>6.6 (0.16)</td>
<td>6.1 (0.18)</td>
<td>−0.0 to 1.0 (F(1,9) = 4.4, P=0.065)</td>
</tr>
<tr>
<td>Lactate (µmol/g wet faeces)</td>
<td>5.6 (1.7)</td>
<td>8.0 (2.0)</td>
<td>−8.6 to 3.6 (F(1,9) = 0.7, P=0.376)</td>
</tr>
<tr>
<td>Total SCFA (µmol/g wet faeces)</td>
<td>97.3 (6.7)</td>
<td>90.6 (7.4)</td>
<td>−15.8 to 29.3 (F(1,9) = 0.5, P=0.517)</td>
</tr>
<tr>
<td>Acetate (% of total SCFA)</td>
<td>62.0 (2.0)</td>
<td>72 (2.2)</td>
<td>−16.9 to −3.3 (F(1,9) = 11.2, P=0.009)</td>
</tr>
<tr>
<td>Propionate (% of total SCFA)</td>
<td>17.5 (1.3)</td>
<td>14.9 (1.4)</td>
<td>−1.9 to 7.0 (F(1,9) = 1.7, P=0.224)</td>
</tr>
<tr>
<td>Butyrate (% of total SCFA)</td>
<td>22.5 (1.2)</td>
<td>15.0 (1.4)</td>
<td>3.4 to 11.7 (F(1,9) = 17.1, P=0.003)</td>
</tr>
</tbody>
</table>
known to occur after the intake of high doses of non-digestible fibres such as FOS (Gibson et al. 1995; Bouhnik et al. 1996; Buddington et al. 1996; Kleessen et al. 1997; Tuohy et al. 2001). Serious adverse events were not reported.

The daily intake of FOS did not affect intestinal epitheliolysis, as indicated by the cytotoxicity of faecal water and the faecal activity of ALP. The cytotoxicity of faecal water is determined by the presence of potential luminal toxic compounds that can harm the intestinal epithelial membrane. ALP is an enzyme that is located within the apical membrane of enterocytes. Damage to the apical membrane or epithelial shedding may result in the release of ALP into the faecal stream, hence ALP can be used as a marker for intestinal epitheliolysis (McNeil & Ito, 1989; Lapre et al. 1991; Bovee-Oudenhoven et al. 1996). Since lysis is determined by the cytotoxicity of luminal contents as well as by the susceptibility of the plasma membrane exposed to these surfactants, a combination of both analyses is relevant for the quantification of epitheliolysis. It was revealed that both the cytotoxicity of faecal water and the activity of ALP in faecal water were not affected by the intake of FOS. Moreover, the cytotoxicity of faecal water tended to be lower in the FOS period compared with the control period, with a mean observed difference of 19·1 % (P = 0·084), indicating a protective effect of FOS against cytotoxic components in the colon.

The susceptibility of the intestinal epithelial membrane to toxic compounds is also determined by the intestinal mucus gel layer covering the intestinal epithelium. The mucus gel layer consists of mucins, which are glycoproteins produced and secreted by goblet cells in the gastrointestinal tract. Many physiological or pathogenic stimuli enhance mucin secretion, which is thought to contribute to the intestinal barrier function, protecting the gastrointestinal mucosa from mechanical, chemical and microbial challenge (Strous & Dekker, 1992). For example, bacterial fermentation products such as acetate are known to support mucoprotection by increasing intestinal mucin expression and secretion (Finnie et al. 1995; Sakata & Setoyama, 1995; Shimotyodome et al. 2000; Willemsen et al. 2003).

On the other hand, changes in the excretion of mucin-type oligosaccharides may also indicate irritation or challenge of the intestinal epithelium. Mucins consist of a protein core, with O-linked oligosaccharide side chains (Strous & Dekker, 1992; Deplancke & Gaskins, 2001). Thus, analysis of O-linked carbohydrates in the faeces gives an estimate of the amount of mucin glycoprotein secreted (Bovee-Oudenhoven et al. 1996). Under normal physiological conditions, mucins can only be detected at low concentrations in the faeces, since both commensal and pathogenic intestinal bacteria are able to ferment shedded mucins (Hoskins, 1981; Hoskins et al. 1985; Deplancke & Gaskins, 2001). Hence, the actual amount of mucin in the faeces is a result of the production, shedding and fermentation of mucins in the gastrointestinal tract.

In our human volunteer study, no significant differences were observed in the excretion of mucin-type oligosaccharides in the faeces between the FOS period and the control period. These results are in agreement with results on the cytotoxicity of faecal water and the activity of ALP. The analysis of mucins in faeces is troublesome, and although the O-glycosylation methods may give an indication of intestinal mucin excretion, such assays are not reliable for estimating intestinal
cell damage. The excretion of mucin in healthy adults was previously studied by Ouwehand et al. (2000), using a colorimetric assay. In this study, the excretion of mucin did not differ between adults consuming a high-fibre diet and those consuming a low-fibre diet. The mean faecal concentration was approximately 6 mg/g wet faeces, which corresponds to a concentration of approximately 24 mg/g dry faeces. In another study, an increased faecal concentration of mucin-type oligosaccharides was observed in healthy males receiving a diet with 20 g of FOS daily for 2 weeks, in combination with a diet restricted in Ca (Ten Bruggencate et al. 2004b).

Our results differ from the results of other studies, in which a higher cytotoxicity of faecal water and an increased excretion of mucin-type oligosaccharides were observed in Ca-restricted rats fed high doses of FOS (Bovee-Oudenhoven et al. 2003; Ten Bruggencate et al. 2003, 2004a), and a higher excretion of mucin-type oligosaccharides was observed in humans receiving 20 g of FOS in combination with a diet restricted in Ca (Ten Bruggencate et al. 2004b). As another recent study by the same group (Ten Bruggencate et al. 2004a) demonstrated that Ca inhibited the irritative effects of FOS in rats, the dietary Ca restriction in the studies mentioned above may have had an adverse effect on the cytotoxicity and/or mucin excretion. In the small intestine, Ca and PO4 form an insoluble complex, which can dissolve in the more acidic environment of the colon. Hence, Ca is known to increase the buffering capacity of the intestinal lumen (Govers & Van der Meer, 1993; Govers et al. 1996), and to bind cytotoxic components, precipitating in the lumen, thereby decreasing the cytotoxic activity in the colon (Govers et al. 1994).

As the present study was performed under habitual dietary conditions, without any dietary Ca restriction, we conclude that dietary FOS in a dose of up to 25–30 g/d, in combination with a regular diet unrestricted in Ca, do not affect the cytotoxicity of faecal water, faecal ALP activity or the faecal concentration of mucin-type oligosaccharides in human adults.

Acknowledgements
The authors would like to thank the volunteers (Wageningen, The Netherlands) who participated in the study, Madelon Brummelhuis (Wageningen University) for the practical execution of the study, Jürgen Jelinek (Friedrichsdorf, Germany) and Rob Verdooren (Wageningen, The Netherlands) for statistical advice, Günther Raffler of the Cen-

References


Downloaded from https://www.cambridge.org/core. IP address: 54.70.40.11, on 08 Dec 2018 at 05:12:59, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. © Cambridge University Press, 2018.


